Us2.ai software was used in the echocardiographic core laboratory analysis of CARDIO-TTRansform, a Phase 3 trial of eplontersen in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The authors describe it as the largest clinical trial in ATTR with cardiomyopathy to date.

 

The trial

CARDIO-TTRansform was a multicenter, randomized, double-blind, placebo-controlled trial. It randomized 1,432 patients with ATTR-CM to eplontersen 45 mg or placebo, administered subcutaneously every 4 weeks. Echocardiography was performed at baseline and at weeks 61, 97, and 140. The present analysis included 1,426 participants with baseline echocardiograms (mean age, 76 years; 91% men; 85% with wild-type disease).

 

Use of Us2.ai software

The authors describe the echocardiographic analysis as follows:

 

Echocardiographic findings

The authors report that eplontersen did not significantly reduce the primary end point of cardiovascular death and recurrent cardiovascular events, and that treatment effects varied by baseline use of TTR stabilizers. In the echocardiographic analysis, baseline measures of left ventricular systolic and diastolic function and of right ventricular function were independently associated with all-cause mortality or the primary end point.

At week 140, compared with placebo, eplontersen attenuated increases in mean left ventricular wall thickness and declines in left ventricular stroke volume, myocardial contraction fraction, average E/e′, and right ventricular outflow tract velocity time integral. The authors state that these effects were driven almost exclusively by patients not receiving stabilizers at baseline, and that no significant treatment effects were observed in patients receiving stabilizers. They conclude that eplontersen "modestly attenuated deterioration" in these measures, and that further studies are needed to determine whether the changes translate into clinical benefit.

 

Us2.ai is proud to see our software used again in a Phase 3 trial of this scale, following HELIOS-B and ACACIA-HCM.


Jering, K. S., Skali, H., Claggett, B., Prasad, N., Chen, J., Gonzalez-Lopez, E., Morbach, C., Cuddy, S. A. M., Davis, M. K., Fernandes, F., Mitchell, J. D., Sarswat, N., Urey, M. A., Platz, E., Tsimikas, S., Maurer, M. S., Fontana, M., & Solomon, S. D. (2026). Effects of eplontersen on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: Insights from the CARDIO-TTRansform trial. Circulation. Advance online publication. https://doi.org/10.1161/CIRCULATIONAHA.126.083722